Navigation Links
Study: Modafinil is effective in treating excessive sleepiness
Date:10/15/2007

WESTCHESTER, Ill. A study published in the October 15 issue of the Journal of Clinical Sleep Medicine (JCSM) finds that modafinil is well-tolerated in the treatment of excessive sleepiness associated with disorders of sleep and wakefulness such as shift work sleep disorder, obstructive sleep apnea (OSA) and narcolepsy, and does not affect cardiovascular or sleep parameters.

The study, authored by Thomas Roth, PhD, of the Henry Ford Sleep Center in Detroit, Mich., focused on 1,529 outpatients who received modafinil 200, 300 or 400 mg, or a placebo once per day for up to 12 weeks. A total of 934 patients received modafinil, and 567 received a placebo. The subjects were assessed for adverse events and effects of modafinil on blood pressure/heart rate, electrocardiogram intervals, polysomnography, and clinical laboratory parameters.

According to the results, modafinil was well tolerated versus a placebo, with headache, nausea and infection the most common adverse side effect. The overall incidence of side effects was similar among the three modafinil dosage groups. Adverse events occurring more frequently in the modafinil group than in controls included headache, nausea, dry mouth, anorexia, nervousness, insomnia, anxiety, hypertension and pharyngitis. In patients taking modafinil, 19 serious adverse events occurred, while in the placebo group, there were 10 serious adverse events.

In modafinil-treated patients clinically significant increases in diastolic or systolic blood pressure were infrequent. In the narcolepsy studies one patient in the modafinil group and one in the placebo group had a clinically significant increase in heart rate.

New clinically meaningful electrocardiogram abnormalities were rare with the modafinil and placebo group.

Modafinil did not affect sleep architecture in any patient population according to polysomnography.

Clinically significant abnormalities in mean laboratory parameters were observed in less than one percent of patients in modafinil-treated patients at the final visit.

Modafinil is well tolerated. Furthermore, it appears from these prospective research studies that daily modafinil administration confers a low risk of adverse events or severe adverse events. These results make for a positive risk-benefit ratio for using modafinil to treat excessive sleepiness in patients with shift work sleep disorder, OSA and narcolepsy, said Dr. Roth.

The American Academy of Sleep Medicine (AASM) recommends that people who suspect that they might have a sleep disorder see a primary care physician or a sleep medicine specialist for proper diagnosis and to discuss treatment options before treatment with medications is undertaken.

While modern hypnotics are considered safe, individuals should be aware that, like all medications, side effects may occur in patients.

Sleep medications are effective and safe treatments when used properly and judiciously by a patient who is under the supervision of a sleep medicine or primary care physician.


'/>"/>

Contact: Jim Arcuri
jarcuri@aasmnet.org
708-492-0930
American Academy of Sleep Medicine
Source:Eurekalert

Related medicine news :

1. Counter study: cholesterol drugs no good in preventing colon cancer
2. A strategic study: Soy diet makes heart disease to worsen in male mice
3. Bird Flu Pandemic Study: Clerical & Support Staff May Stay At Home
4. Study: Older Pancreatic Cancer Surgery Survivors Live Long
5. New Study: Pine Bark Significantly Reduces Endometriosis
6. New Way to "See" Genes, Evaluate Effectiveness of Gene Therapies Discovered
7. Inhaled Steroids Safe & Effective for Children with Asthma
8. Morning after pill effective up to five days after having unprotected sex
9. Distraction therapy found very effective in postoperative patients
10. ZD1839 Proves Effective - A Breakthrough in fighting Lung Cancer
11. TELITHROMYCIN - the proven effective new drug for cap
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... May 31, 2016 , ... In his latest video, ... traits in humans. Using presidential candidate Donald Trump as an example, Kalsi describes ... “AstroNumerology is not about adding numbers up,” says Kalsi. “It is about looking ...
(Date:5/31/2016)... , ... May 31, 2016 , ... Phynd Technologies, Inc. ... GA; Houston Methodist – Houston, TX and Shore Medical Center – Somers Point, NJ. ... three different, leading EHR solutions, demonstrating the breadth of Phynd’s solution and its interoperability. ...
(Date:5/31/2016)... ... May 31, 2016 , ... Dr. Charles A. Ditta ... of New Jersey in the class of 1986, where he graduated in the top ... his current location in Livingston since 1989. He has been a member in good ...
(Date:5/31/2016)... ... ... Super Powder, a supplement produced by Prox Formulas for providing protein ... to transform the nutritional supplement industry by providing a safe, natural approach to enhanced ... (BCAA), alkaline minerals, wheat grass, digestive enzymes, Omega 3’s, Vit D3, Vit A, B1, ...
(Date:5/30/2016)... ... May 30, 2016 , ... ... Shaolin warrior 8-day-8 and 8-night special intensive summer training camp starts on June ... summer camp offers families and children a fun and unique experience with an ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... 2016 According to the 2016 ... driving ambulatory blood pressure monitoring system market growth. With ... ability to respond to different pressure rates, leading to ... to various cardiovascular disorders such as heart failure, stroke, ... are growing in prevalence each year. WHO estimates that ...
(Date:5/26/2016)... May 26, 2016 According to a ... Management Market - U.S. Industry Analysis, Size, Share, Growth, Trends, ... in the U.S. was valued at US$ 5.89 Bn in ... 3.4% from 2015 to 2023 to reach US$ 7.99 Bn ... current and emerging needle free drug delivery devices and the ...
(Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
Breaking Medicine Technology: